Last reviewed · How we verify
NCT06916715
MR Elastography in Intracranial Lesions: Feasibility & Accuracy
trial in Brain Neoplasms in 512 participants. Participants enrolled and being followed up; not accepting new ones.
9 December 2025
Quick facts
| Lead sponsor | Shengjing Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 512 |
| Start date | 9 May 2017 |
| Primary completion | 9 December 2025 |
| Estimated completion | 9 December 2026 |
| Sites | 1 location across China |
Conditions studied
- Brain Neoplasms — all drugs for Brain Neoplasms →
Sponsor
Shengjing Hospital
Who can join
Adults 8 to 83, any sex, with Brain Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Brain tumors, despite their relatively low incidence among cancers, are associated with high morbidity and mortality due to the brain's complexity. Biopsy, the gold standard for tumor grading, is limited by invasiveness, costs, and sampling issues. Conventional MR imaging lacks sensitivity to differentiating tumor grades, while magnetic resonance elastography (MRE) offers non-invasive assessment potential. This retrospective study reviewed MRE data from 512 brain tumor patients (May 2017-December 2024) to evaluate MRE's diagnostic performance, success rate in tumor grading, and clinical reliability, aiming to advance its role in non-invasive brain tumor assessment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06916715
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Brain Neoplasms
Currently open trials in the same condition.
- NCT07272616 — Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison · recruiting
- NCT07426848 — OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients · NA · recruiting
- NCT07111182 — Intraoperative Fluorescence-Guided Aspirate Tissue Monitoring of 5-ALA During Brain Tumor Surgery · NA · recruiting
- NCT07238322 — [18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes · active not recruiting
- NCT06165653 — Guided Meditation During Radiation Therapy for Brain Tumors · NA · recruiting
Other Shengjing Hospital trials
Trials by the same sponsor.
- NCT07484763 — Predicting Recurrence in HR+/HER2- Early Breast Cancer · not yet recruiting
- NCT07497191 — AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast Cancer · not yet recruiting
- NCT07320599 — Neuroendoscopic Surgery With Ommaya Reservoir Implantation vs. Burr Hole Drainage for Infantile Postmeningitis Subdural · not yet recruiting
- NCT07153783 — Interventional AI-Human Collaboration for Liver Tumor Diagnosis · NA · completed
- NCT07101614 — A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chem · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06916715 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shengjing Hospital
- Last refreshed: 9 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06916715.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing